Get the Stockscreener App
21.45
0.19%
-0.04
Denali Therapeutics Inc Stock (DNLI) Forecast
The Denali Therapeutics Inc (DNLI) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $12.25, representing a -42.87% decrease from the current price of $21.45. The highest analyst price target is $14.32, and the lowest is $10.19.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month DNLI Price Target
Average 24.56
(+14.49% Upside)
Is Denali Therapeutics Inc (DNLI) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 31.46 | Neutral |
| STOCH(9,6) | 13.65 | Buy |
| STOCHRSI(14) | 2.2282 | Buy |
| MACD(12,26) | -1.178 | Sell |
| ADX(14) | 14.96 | Neutral |
| William %R | -87.27 | Buy |
| CCI(14) | -113.19 | Sell |
Buy: 3
Sell: 2
Neutral: 2
Summary: Buy
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
23.06
Sell
|
22.74
Sell
|
| MA20 |
23.80
Sell
|
23.71
Sell
|
| MA50 |
25.88
Sell
|
25.10
Sell
|
| MA100 |
25.99
Sell
|
25.09
Sell
|
| MA200 |
23.09
Sell
|
23.97
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, DNLI could be considered a Strong Sell, with 17 technical analysis indicators signaling 3 Buy signals, 12 signaling Sell signals and 2 Neutral signals. This might not be a good time to consider opening new positions on DNLI, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 31.46 indicates that DNLI is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 13.65 indicates that DNLI is oversold. This indicates that DNLI price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 2.2282 indicates that DNLI is oversold. This suggests that DNLI price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 14.96 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -113.19 indicates that DNLI is oversold. This means that the price has moved significantly lower than its average, indicating a potential buying opportunity.
Long-term DNLI price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Denali Therapeutics Inc financial reports and earnings history, Denali Therapeutics Inc (DNLI) stock could reach $10.19 by 2030, $11.45 by 2040 and $9.8426 by 2050. See the projected annual prices until 2050 of the Denali Therapeutics Inc stock below:
- Denali Therapeutics Inc (DNLI) is expected to reach an average price of $9.2921 in 2035, with a high prediction of $13.33 and a low estimate of $6.3209. This indicates an $-56.68% rise from the last recorded price of $21.45.
- Denali Therapeutics Inc (DNLI) stock is projected to chart a bullish course in 2040, with an average price target of $10.59, representing an $-50.62% surge from its current level. The forecast ranges from a conservative $8.4185 to a sky-high $11.45.
- Our analysts predict Denali Therapeutics Inc (DNLI) to jump -48.66% by 2045, soaring from $6.1196 to an average price of $11.01, potentially reaching $14.07. While $6.1196 is the low estimate, the potential upside is significant.
- Denali Therapeutics Inc (DNLI) stock is expected to climb by 2050, reaching an average of $9.5326, a $-55.56% jump from its current level. However, a wide range of estimates exists, with high and low targets of $9.8426 and $3.1626, respectively, highlighting the market's uncertainty.
Denali Therapeutics Inc Stock (DNLI) Year by Year Forecast
Denali Therapeutics Inc Stock (DNLI) Price Forecast for 2025
Denali Therapeutics Inc Stock (DNLI) is expected to reach an average price of $24.56 in 2025, with a high prediction of $41.60 and a low estimate of $7.5147. This indicates an +14.49% rise from the last recorded price of $21.45.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $10.26 | $10.19 | $14.32 | -52.18% |
| February, 2025 | $17.32 | $10.20 | $24.54 | -19.28% |
| March, 2025 | $13.58 | $13.04 | $20.77 | -36.70% |
| April, 2025 | $11.48 | $7.5147 | $14.80 | -46.50% |
| May, 2025 | $14.81 | $9.9715 | $15.41 | -30.96% |
| June, 2025 | $16.93 | $14.36 | $20.15 | -21.07% |
| July, 2025 | $18.10 | $17.34 | $23.69 | -15.62% |
| August, 2025 | $20.26 | $17.56 | $21.91 | -5.54% |
| September, 2025 | $25.96 | $16.70 | $30.05 | +21.04% |
| October, 2025 | $25.24 | $22.98 | $29.26 | +17.68% |
| November, 2025 | $30.23 | $24.62 | $33.61 | +40.95% |
| December, 2025 | $37.21 | $30.34 | $41.60 | +73.48% |
Denali Therapeutics Inc Stock (DNLI) Price Forecast for 2026
The predicted value for Denali Therapeutics Inc (DNLI) in 2026 is set at an average of $62.48. Estimates vary from a peak of $88.42 to a trough of $36.54, indicating an +191.28% surge from the present price of $21.45.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $55.72 | $36.54 | $66.44 | +159.79% |
| February, 2026 | $80.04 | $54.17 | $80.48 | +273.13% |
| March, 2026 | $67.53 | $59.06 | $88.42 | +214.82% |
| April, 2026 | $59.81 | $55.84 | $78.50 | +178.82% |
| May, 2026 | $56.56 | $50.15 | $67.05 | +163.68% |
| June, 2026 | $46.83 | $45.27 | $58.53 | +118.33% |
| July, 2026 | $48.50 | $43.80 | $58.54 | +126.11% |
| August, 2026 | $69.62 | $46.85 | $69.91 | +224.58% |
| September, 2026 | $66.89 | $62.32 | $74.34 | +211.84% |
| October, 2026 | $46.79 | $41.69 | $68.08 | +118.15% |
| November, 2026 | $47.90 | $42.86 | $50.00 | +123.29% |
| December, 2026 | $45.17 | $43.74 | $51.50 | +110.60% |
Denali Therapeutics Inc Stock (DNLI) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Denali Therapeutics Inc (DNLI) is $33.00, with a high forecast of $50.84 and a low forecast of $15.17. This indicates an +53.87% increase from the last price of $21.45.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $42.59 | $38.62 | $47.72 | +98.54% |
| February, 2027 | $41.88 | $41.25 | $50.84 | +95.24% |
| March, 2027 | $42.07 | $35.89 | $42.89 | +96.11% |
| April, 2027 | $29.66 | $25.07 | $43.26 | +38.27% |
| May, 2027 | $28.67 | $25.34 | $30.97 | +33.67% |
| June, 2027 | $25.32 | $25.11 | $33.39 | +18.04% |
| July, 2027 | $27.06 | $23.64 | $30.32 | +26.16% |
| August, 2027 | $21.66 | $21.41 | $30.52 | +1.00% |
| September, 2027 | $20.17 | $15.17 | $22.53 | -5.96% |
| October, 2027 | $18.86 | $15.72 | $20.96 | -12.05% |
| November, 2027 | $29.06 | $19.29 | $30.09 | +35.46% |
| December, 2027 | $33.13 | $26.67 | $34.45 | +54.43% |
Denali Therapeutics Inc Stock (DNLI) Price Forecast for 2028
In 2028, Denali Therapeutics Inc (DNLI) is projected to reach an average price of $25.26, with a high projection of $33.56 and a low estimate of $16.97. This indicates an +17.78% rise from the last price of $21.45.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $22.87 | $21.85 | $33.56 | +6.61% |
| February, 2028 | $25.75 | $20.94 | $28.89 | +20.05% |
| March, 2028 | $23.77 | $21.19 | $29.86 | +10.81% |
| April, 2028 | $25.08 | $21.61 | $27.82 | +16.92% |
| May, 2028 | $23.01 | $21.10 | $28.12 | +7.27% |
| June, 2028 | $24.23 | $21.36 | $26.07 | +12.96% |
| July, 2028 | $24.31 | $23.72 | $27.99 | +13.35% |
| August, 2028 | $18.43 | $17.49 | $25.95 | -14.07% |
| September, 2028 | $19.51 | $16.97 | $19.60 | -9.03% |
| October, 2028 | $21.78 | $18.45 | $22.37 | +1.52% |
| November, 2028 | $26.80 | $21.28 | $28.03 | +24.96% |
| December, 2028 | $24.82 | $23.56 | $28.61 | +15.69% |
Denali Therapeutics Inc Stock (DNLI) Price Forecast for 2029
The 2029 price forecast for Denali Therapeutics Inc Stock (DNLI) is $17.84 on average, with a high prediction of $26.11 and a low estimate of $9.56. This represents an -16.85% decrease from the previous price of $21.45.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $23.76 | $22.88 | $26.11 | +10.79% |
| February, 2029 | $18.38 | $17.31 | $23.69 | -14.33% |
| March, 2029 | $18.93 | $17.61 | $20.54 | -11.75% |
| April, 2029 | $16.16 | $14.96 | $19.18 | -24.65% |
| May, 2029 | $11.65 | $11.35 | $17.91 | -45.69% |
| June, 2029 | $14.42 | $10.89 | $15.03 | -32.76% |
| July, 2029 | $16.93 | $13.33 | $19.27 | -21.05% |
| August, 2029 | $11.51 | $11.40 | $17.41 | -46.33% |
| September, 2029 | $12.46 | $11.00 | $14.45 | -41.93% |
| October, 2029 | $15.17 | $12.07 | $19.05 | -29.26% |
| November, 2029 | $11.58 | $11.49 | $16.60 | -46.03% |
| December, 2029 | $10.11 | $9.56 | $12.78 | -52.87% |
Denali Therapeutics Inc Stock (DNLI) Price Forecast for 2030
Denali Therapeutics Inc Stock (DNLI) is expected to reach an average price of $10.23 in 2030, with a high forecast of $18.73 and a low forecast of $1.7393. This signifies an -52.30% decrease from the last price of $21.45.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $6.7561 | $6.2249 | $10.19 | -68.50% |
| February, 2030 | $8.1209 | $6.6773 | $9.9497 | -62.14% |
| March, 2030 | $7.3007 | $7.1357 | $10.27 | -65.96% |
| April, 2030 | $6.0506 | $5.4882 | $8.1082 | -71.79% |
| May, 2030 | $3.4666 | $3.4466 | $7.9242 | -83.84% |
| June, 2030 | $4.5315 | $2.4203 | $4.6265 | -78.87% |
| July, 2030 | $6.0975 | $2.7505 | $6.2575 | -71.57% |
| August, 2030 | $8.0974 | $5.12 | $8.3824 | -62.25% |
| September, 2030 | $7.0172 | $4.351 | $8.4736 | -67.29% |
| October, 2030 | $13.85 | $5.8484 | $18.73 | -35.42% |
| November, 2030 | $3.7681 | $2.3781 | $14.97 | -82.43% |
| December, 2030 | $5.423 | $1.7393 | $8.2168 | -74.72% |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):